This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
Recent marketing of several new antiarthritic medications, with the associated media fanfare and "education" seminars for physicians creates a concern that I would like to express. As competition between these nonsteroidal antiinflammatory agents intensifies, the public is subjected to glowing reports in the media, in turn leading to a barrage of phone calls to the physician treating arthritic patients. What the public fails to comprehend is that most of these drugs are similar in structure or mechanism of action to others with which they are already familiar and, more often than not, offer no advantage in efficacy. They do offer a unit cost that I frankly find to be somewhat astounding, and without debating the economics of drug marketing I would like to register this concern.Having participated in seminars sponsored by drug companies, it is with trepidation that I offer my final concern, that the wooing
Rochmis PG. Seminars for Physicians. JAMA. 1982;248(13):1580–1581. doi:10.1001/jama.1982.03330130028017
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: